Chronic Immune Thrombocytopenia
Hematology·MeSH: Purpura
Prevalence
30.0 / 100K
8 drugs in development·5 companies·3 clinical trials
Drug Pipeline by Phase
Approved(4)
Phase 3(1)
| Drug | Company |
|---|---|
| bms-986393 | Juno Therapeutics, Inc. (JUNO) |
Phase 2(1)
| Drug | Company |
|---|---|
| bms-986353 | Juno Therapeutics, Inc. (JUNO) |
Phase 1(1)
| Drug | Company |
|---|---|
| fludarabine | Juno Therapeutics, Inc. (JUNO) |
Phase 1/Phase 2(1)
| Drug | Company |
|---|---|
| cid-103 | CASI Pharmaceuticals, Inc. (CASIF) |
Compare drugs
Frequently asked questions
How many drugs are in development for Chronic Immune Thrombocytopenia?
BioSniper tracks 8 drugs in development for Chronic Immune Thrombocytopenia across 5 companies.
How many clinical trials target Chronic Immune Thrombocytopenia?
There are 3 clinical trials targeting Chronic Immune Thrombocytopenia tracked by BioSniper.
What is the prevalence of Chronic Immune Thrombocytopenia?
The estimated prevalence of Chronic Immune Thrombocytopenia is approximately 30.0 per 100,000 population.
Deep-dive into Chronic Immune Thrombocytopenia
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis